Quick Answer
Inhibikase Therapeutics, Inc. reported Diluted EPS of $0.49 per share (loss) for fiscal year 2025.
Inhibikase Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.49 | +57.8% |
| 2024 | -$1.16 | +63.3% |
| 2023 | -$3.16 | +26.2% |
| 2022 | -$4.28 | -428.4% |
| 2021 | -$0.81 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.13 | +80.0% | -18.2% |
| June 30, 2025 | -$0.11 | +83.3% | +26.7% |
| March 31, 2025 | -$0.15 | +79.5% | +76.9% |
| September 30, 2024 | -$0.65 | +24.4% | +1.5% |
| June 30, 2024 | -$0.66 | +40.5% | +9.6% |
| March 31, 2024 | -$0.73 | +25.5% | +15.1% |
| September 30, 2023 | -$0.86 | +18.9% | +22.5% |
| June 30, 2023 | -$1.11 | -0.9% | -13.3% |
- Inhibikase Therapeutics, Inc. showed an increase of +57.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Inhibikase Therapeutics, Inc.’s diluted eps has grown by 39.5% (from $0.81 per share (loss) to $0.49 per share (loss)).
- The most recent figure is from Inhibikase Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: